967 related articles for article (PubMed ID: 25524389)
1. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
LaMori JC; Shoheiber O; Mody SH; Bookhart BK
Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
3. The Incidence and Economic Burden of In-Hospital Venous Thromboembolism in the United States.
Shahi A; Chen AF; Tan TL; Maltenfort MG; Kucukdurmaz F; Parvizi J
J Arthroplasty; 2017 Apr; 32(4):1063-1066. PubMed ID: 27866951
[TBL] [Abstract][Full Text] [Related]
4. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
5. Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.
Lang K; Patel AA; Munsell M; Bookhart BK; Mody SH; Schein JR; Menzin J
J Thromb Thrombolysis; 2015 May; 39(4):434-42. PubMed ID: 25079971
[TBL] [Abstract][Full Text] [Related]
6. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
Dasta JF; Pilon D; Mody SH; Lopatto J; Laliberté F; Germain G; Bookhart BK; Lefebvre P; Nutescu EA
Thromb Res; 2015 Feb; 135(2):303-10. PubMed ID: 25555319
[TBL] [Abstract][Full Text] [Related]
7. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
8. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
Spyropoulos AC; Lin J
J Manag Care Pharm; 2007; 13(6):475-86. PubMed ID: 17672809
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.
MacDougall DA; Feliu AL; Boccuzzi SJ; Lin J
Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S5-15. PubMed ID: 17032933
[TBL] [Abstract][Full Text] [Related]
10. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
11. Inpatient and outpatient occurrence of deep vein thrombosis and pulmonary embolism and thromboprophylaxis following selected at-risk surgeries.
Amin AN; Lin J; Thompson S; Wiederkehr D
Ann Pharmacother; 2011 Sep; 45(9):1045-52. PubMed ID: 21862717
[TBL] [Abstract][Full Text] [Related]
12. Hospital charges associated with "never events": comparison of anterior cervical discectomy and fusion, posterior lumbar interbody fusion, and lumbar laminectomy to total joint arthroplasty.
Daniels AH; Kawaguchi S; Contag AG; Rastegar F; Waagmeester G; Anderson PA; Arthur M; Hart RA
J Neurosurg Spine; 2016 Aug; 25(2):165-9. PubMed ID: 26989978
[TBL] [Abstract][Full Text] [Related]
13. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
14. National trends in hospitalizations for venous thromboembolism.
Brahmandam A; Abougergi MS; Ochoa Chaar CI
J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):621-629.e2. PubMed ID: 28818212
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
Mahan CE; Borrego ME; Woersching AL; Federici R; Downey R; Tiongson J; Bieniarz MC; Cavanaugh BJ; Spyropoulos AC
Thromb Haemost; 2012 Aug; 108(2):291-302. PubMed ID: 22739656
[TBL] [Abstract][Full Text] [Related]
16. Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events.
Nutescu EA; Crivera C; Schein JR; Bookhart BK
Int J Clin Pract; 2015 Mar; 69(3):321-7. PubMed ID: 25395271
[TBL] [Abstract][Full Text] [Related]
17. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.
Ollendorf DA; Vera-Llonch M; Oster G
Am J Health Syst Pharm; 2002 Sep; 59(18):1750-4. PubMed ID: 12298113
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of hospitalization costs for 278 venous thromboeboembolism patients with health insurance in China].
Wu JJ; Yang L
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 45(3):437-42. PubMed ID: 23774924
[TBL] [Abstract][Full Text] [Related]
20. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
